Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD
Overview
This post-hoc analysis from the KRONOS study explores the effects of triple therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF) compared to dual therapies on lung function and exacerbations in COPD patients without asthma diagnosis. The focus is on blood eosinophil count and exacerbation history.
Practical Solutions
For patients with moderate-to-very severe COPD, consideration of a step-up to triple therapy may be beneficial, especially for those with persistent/worsening symptoms and a blood eosinophil count > 100 cells/mm3, even in the absence of recent exacerbations.
Value
These findings suggest potential benefits of BGF over other therapies, including lung function improvements and reduced exacerbation rates, particularly for patients without recent exacerbations and those with moderate to severe COPD.
Additional Information
The KRONOS study was not originally designed for these specific analyses, indicating the need for further investigation in future studies.
Conclusion
Clinicians may find this analysis useful in guiding treatment decisions for COPD patients, providing insight into the potential advantages of triple therapy in specific patient populations.
